Levofloxacin, the L-isomer of ofloxacin, is approximately twice as active as ofloxacin against most Gram-positive and Gram-negative bacteria, and has improved intracellular pharmacokinetic and pharmacodynamic properties. The present work deals with the in-vitro activity of levofloxacin against the obligate intracellular bacteria Rickettsia rickettsii, Rickettsia conorii, 'Israeli spotted fever group rickettsia' (Israeli SFGR) and Coxiella burnetii. Fluoroquinolones, including ofloxacin, have previously been shown to be bacteriostatic against Rickettsia spp. and C. burnetii in vitro. They are reliable alternatives to tetracycline therapy for Mediterranean spotted fever, scrub typhus and acute Q fever. Levofloxacin was bacteriostatic against R. rickettsii, R. conorii and the Israeli SFGR at concentrations of 0.5-1 mg/L, as determined by both a plaque assay and a dye uptake assay. It was also bacteriostatic against C. burnetii isolates, including the Nine Mile, Priscilla and Q212 strains, at concentrations of 0.5-2 mg/L, as determined using the shell vial assay. Overall, levofloxacin could inhibit rickettsial growth at concentrations equal to or half of those necessary for growth inhibition by ofloxacin. Levofloxacin was not bactericidal against C. burnetii at concentrations up to 4 mg/L.
Introduction
Rickettsia rickettsii, Rickettsia conorii and the 'Israeli spotted fever group rickettsiae' (Israeli SFGR) are, respectively, the aetiological agents of Rocky Mountain spotted fever, Mediterranean spotted fever and spotted fever without 'taches noires' in Israel, 1 all of them being tickborne diseases. Coxiella burnetti is the aetiological agent of Q fever, a widely distributed zoonosis, which may present acutely as pneumonitis and hepatitis, or chronically, typically as endocarditis. Bacteria of the genera Rickettsia and Coxiella are strict intracellularly-living organisms. Rickettsia spp. grow within the cytoplasm of infected cells, 2 whereas C. burnetti grows within phagolysosomes, at acidic pH. 3 Although tetracyclines remain the first-line antibiotics to treat rickettsial diseases, alternatives may be required in the event of tetracycline intolerance or contra-indication. The macrolides have been reported to display variable in-vitro activity against R. conorii, R. rickettsii, Orientia tsutsugamushi, ELB rickettsiae and C. burnetti. [4] [5] [6] Erythromycin is not a safe alternative for rickettsial diseases.
Josamycin has been used successfully in patients with Mediterranean spotted fever. Clinical data on the effectiveness of newer macrolides, including azithromycin and clarithromycin, are lacking. Fluoroquinolones have been previously reported to be effective rickettsial agents both in vitro 5, [7] [8] [9] [10] [11] [12] and in vivo, in patients with Mediterranean spotted fever [13] [14] [15] [16] [17] [18] or acute Q fever. 16, 19 Levofloxacin, the L929 murine fibroblast cells. 5 Infected cells were grown in minimal essential medium (MEM) supplemented with 10% fetal calf serum and 2 mM glutamine.
Antibiotics
Levofloxacin (Roussel Uclaf, Romainville, France) and ofloxacin (Diamant, Puteaux, France) were dissolved in methanol and then diluted in sterile distilled water. Aliquots of a stock solution (1 mg/mL) were frozen at 80°C until required. Aliquots were quickly thawed and the antibiotic solution was incorporated into MEM medium for antibiotic challenges.
Antibiotic susceptibility testing
In all experiments ofloxacin was tested in parallel to levofloxacin and the activity of both drugs was compared.
Plaque assay. The bacteriostatic activity of levofloxacin on R. rickettsii, R. conorii and the Israeli SFGR were evaluated using the plaque assay previously described. 10, 24 Briefly, Petri dishes (60 mm diameter, Corning, NY, USA) were filled with 5 mL of Vero cell-containing MEM medium (4% fetal calf serum, 2 mM glutamine), and incubated (37°C, 5% CO 2 ) until cell confluence. The incubation medium was then replaced with a 1 mL inoculum of 10 4 , 10 3 or 10 2 pfu rickettsiae. After rocking the Petri dishes for 1 h at 37°C, infected cells were overlaid with 5 mL of MEM containing 4% fetal calf serum and 0.5% agar. Two Petri dishes filled with either 10 4 , 10 3 or 10 2 pfu rickettsiae served as drug-free controls. Levofloxacin or ofloxacin was added in the other Petri dishes containing 10 4 pfu before agar was solidified at final concentrations of 0.06-4 mg/L. Petri dishes were incubated (37°C, 5% CO 2 ) for 10 days. The agar was then gently discarded after adding 10% chloroform to fix the cells as previously described, and 1 mL of 1% Crystal Violet was added to allow visualization of the plaques. The MIC corresponded to the lowest antibiotic concentration in the incubation medium of infected cell cultures allowing inhibition of plaque formation (i.e. number of plaques number of plaques in the 10 2 pfu control). Experiments were carried out in duplicate.
Dye uptake assay. The MICs of levofloxacin and ofloxacin for R. rickettsii, R. conorii and the Israeli SFGR were also determined using the dye uptake assay. 10 Briefly, 10 4 Vero cells were dispensed (100 L/well) in 96-well, fla t -b o t t o m e d microtitre plates (CEO, Nancy, France) which were incubated for 1 h (37°C, 5% CO 2 ) to allow cell adherence. Each plate allowed testing of antibiotic susceptibility of one rickettsial strain. No rickettsiae were added in the first row, which served as uninfected-cell controls, and in the twelfth row, which received 0.5-4 mg/L of levofloxacin or ofloxacin to assess the cytotoxicity of the drugs. Dilutions of a 4 10 4 pfu/mL rickettsial inoculum were added to the other wells (50 L/well), so as to obtain 2000 pfu, except in row 3 (200 pfu) and row 4 (20 pfu). After incubation of the plates for 1 h (37°C, 5% CO 2 ), ofloxacin or levofloxacin (0.06-4 mg/L) was added to rows 5-11. The plates were incubated for 4 days (37°C, 5% CO 2 ). Then, cell monolayers were stained with Neutral Red as previously described. The optical density at 492 nm of the solution was determined using a spectrophotometer (Flow Laboratories, McLean, VA, USA). The MIC was the lowest antibiotic concentration for which the mean optical density at 492 nm of the row was less than or equal to the mean optical density of the row containing 20 pfu per well. Experiments were made twice for confirmation of the results.
Acute C. burnetii-infection model: the shell vial assay. The bacteriostatic activity of levofloxacin against the Nine Mile, Priscilla and Q212 strains of C. burnetii was evaluated using the shell vial assay. 5 Briefly, a C. burnetii inoculum that resulted in 30-50% infected HEL cells cultured in shell vials after 6 days' incubation, was prepared for each strain as previously described. The antibiotic challenge was performed by inoculating a series of HEL-containing shell vials with the C. burnetii inoculum. Shell vials were incubated for 1 h (37°C, 5% CO 2 ), then levofloxacin or ofloxacin was incorporated into the incubation medium at concentrations ranging from 0.06 to 4 mg/L. Shell vials without antibiotics served as growth controls. Bacterial growth was evaluated after 6 days' incubation of shell vials by using the IFA technique with a locally prepared rabbit anti-C. burnetii serum and a goat anti-rabbit immunoglobulin (ref. 111-095-003, Immunotech). The percentage of infected cells in HEL monolayers was assessed at 100 magnification by counting at least 200 cells. The results were scored as follows: resistant, growth comparable to that of the drug-free control; intermediately susceptible, 10% infected cells; susceptible, no infected cells. The experiments were performed in duplicate, and repeated to confirm the results.
Chronic C. burnetii-infection model: the L929 cell bactericidal model. The chronically infected L929-cell model previously described was used. 25 Briefly, L929 cells persistently infected with C. burnetii Nine Mile strain were harvested and dispensed in shell vials. During antibiotic challenges cell division was blocked by adding 1 mg/L cycloheximide to the culture medium. On day 0 of the experiments, levofloxacin at concentrations of 1, 2 or 4 mg/L, or ofloxacin at a concentration of 1 mg/L was added to the incubation medium (eight shell vials per drug concentration). The percentage of infected cells in antibiotic-containing cultures was determined using the IFA technique previously described, before antibiotics were added, and after 3, 5, 7 and 10 days of antibiotic exposure, and compared with the percentage of infected cells in drug-free controls. Experiments were duplicated to confirm the results.
Chronic C. burnetii-infection model: a quantitative bactericidal model. The bactericidal activity of levofloxacin against C. burnetii Nine Mile strain was evaluated using a quantitative model previously described. 26 Briefly, L929 cells chronically infected with C. burnetii Nine Mile strain (6 months' infection at the beginning of the experiments) were dispensed into 25 cm 2 flasks (5 mL each) so that each flask received the same primary inoculum. After 1 h incubation of the flasks (37°C, 5% CO 2 ) to allow cell attachment, levofloxacin 1 mg/L or ofloxacin 1 mg/L was added to the culture medium, whereas flasks without antibiotic served as growth controls. After 24 h incubation, the cell monolayer from each flask was harvested, cells were lysed by thermic shock ( 170°C, 37°C), cell lysates were centrifuged at 10,000 rpm and the antibiotic-containing medium was replaced with the same volume of drug-free MEM. Viable organisms from each cell lysate was determined by using the shell vial technique previously described, 5 and were recorded as infecting units per mL (IU/mL). Bactericidal activity corresponded to a significant reduction in bacterial titres (using Student's t-test at the 95% confidence limit) after antibiotic exposure compared with that in the primary inoculum dose, which was determined on day 0 of the experiment using the same procedure. The bactericidal assays were done in triplicate to confirm the results.
Results
Levofloxacin was not toxic for L929 or HEL cells at concentrations of up to 4 mg/L. When antibiotic susceptibility of rickettsiae to levofloxacin was studied, MIC determinations were reproducible using either the plaque assay or the dye uptake assay. As determined by the plaque assay, the MICs of levofloxacin were 0.5, 0.5 and 1 mg/L for R. rickettsii, R. conorii and the Israeli SFGR, respectively. MICs of ofloxacin, as determined by the plaque assay, were 1 mg/L for each of the three species. When using the dye uptake assay, MICs of levofloxacin were 1, 0.5 and 0.5 mg/L for R. rickettsii, R. conorii and the Israeli SFGR, respectively, whereas MICs of ofloxacin were 2, 0.5 and 1 mg/L for the same species. Results are summarized in Table I .
Complete C. burnetii growth inhibition was obtained, in the shell vial method, with levofloxacin at concentrations of 0.5, 1 and 2 mg/L for the Nine Mile, Priscilla and Q212 strains, respectively (Table II) . Ofloxacin was bac- 
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Discussion
Levofloxacin has been reported previously, as being twice as active as ofloxacin against a range of bacteria, including Staphylococcus aureus, coagulase-negative staphylococci,
S t r e p t o c o c c u s spp., most Enterobacteriaceae, P s e u d o m o n a s spp., Haemophilus influenzae, Neisseria gonorrhoeae, Legionella pneumophila, Mycobacterium tuberculosis and
Mycobacterium leprae. [20] [21] [22] [23] [27] [28] [29] [30] On the other hand, levofloxacin has shown improved pharmacokinetic properties within cells when compared with ofloxacin, 23, 30 and in-vitro activity of levofloxacin was greater than that of ofloxacin against intracellular M. tuberculosis 30 and intracellular S. aureus. 23 The aim of the present study was to determine in-vitro activity of levofloxacin against the obligate intracellular organisms R. rickettsii, R. conorii, the Israeli SFGR and C. burnetii. In this study, cell-culture systems were used with which antibiotic susceptibility of rickettsiae had been previously evaluated. 5, [8] [9] [10] [11] [24] [25] [26] [31] [32] [33] [34] [35] Results so obtained correlated well with clinical data on the efficacy of antibiotic therapy for rickettsial diseases.
R. rickettsii, R. conorii and the Israeli SFGR displayed MICs of 0.5-1 mg/L levofloxacin, and 0.5-2 mg/L ofloxacin. In-vitro activity of fluoroquinolones against rickettsial agents has been previously investigated. Pefloxacin and ciprofloxacin were effective against R. rickettsii and R. conoriiusing an embryonated egg model. 8, 9 Introduction of the plaque and the dye uptake assays allowed determination of MICs against Rickettsia spp., mainly those of the spotted fever group rickettsiae, which are summarized in Table I . Clinical data support the in-vitro susceptibility of rickettsiae to fluoroquinolones. Pefloxacin (400 mg bd, mean duration 11 days), either alone or in combination with rifampicin in severe cases, was used successfully to treat patients suffering Mediterranean spotted fever, including two patients with neuromeningeal complications. 16 Ciprofloxacin was used successfully in five patients involved with Mediterranean spotted fever, including an HIV-infected drug addict. 17 Ciprofloxacin was also compared with doxycycline in the treatment of Mediterranean spotted fever using a randomized double-blind evalua- tion. 15 Although doxycycline yielded a more rapid defervescence than ciprofloxacin (2.5 1.06 days versus 3.8 2.1 days), and clinical manifestations such as headache, arthralgia and myalgia resolved more rapidly, ciprofloxacin was considered as an effective alternative. Apyrexia was obtained in an average of 3 2.4 days with ofloxacin (200 mg bd, mean duration 10 days) in 15 patients with Mediterranean spotted fever. 13 One patient suffering from encephalitis was cured with ofloxacin, whereas tetracycline therapy had failed. Activity of ciprofloxacin was comparable to that of chloramphenicol in a murine model of scrub typhus. 36 MICs for C. burnetii Nine Mile, Priscilla and Q212 strains were 0.5-2 mg/L of levofloxacin and 1-2 mg/L of ofloxacin. The effectiveness of fluoroquinolones against C. burnetii was first demonstrated in the embryonated egg model. 11 Using cell culture systems, ciprofloxacin, 7,12 difloxacin, 12 ofloxacin, 11 perfloxacin, 7 fleroxacin, 7 and sparfloxacin, 25 were shown to be bacteriostatic against C. burnetii. Introduction of the shell vial assay 5 allowed more rapid determination of antibiotic susceptibility of multiple strains of C. burnetii against several antibiotics. Experimental data using the shell vial method are summarized in Table II . Pefloxacin (400 mg bd, mean duration 20 days), either alone or combined with rifampicin, was effective in the treatment of six acute Q fever patients, suffering from hepatitis, associated with atypical pneumonia in two cases. 16 Levofloxacin at concentrations up to 4 mg/L was not bactericidal against C. burnetii Nine Mile strain. Such results were in accordance with previous experiments showing that tetracyclines, rifampicin and the fluoroquinolones, which are the antibiotics currently used to treat chronic Q fever, are not bactericidal in vitro. 26 Fluoroquinolones combined with doxycycline are one of the most reliable antibiotic regimens for effective treatment of chronic Q fever endocarditis. 37 However, clinical reports indicate the difficulty of C. burnetii eradication in chronically infected patients even when prolonged antibiotic therapy has been administered. 19, 37 In conclusion, although the tetracyclines remain the firstline antibiotic therapy for rickettsiosis, fluoroquinolones, including ofloxacin, represent an effective alternative in the treatment of Mediterranean spotted fever and acute Q fever diseases. Overall, levofloxacin was equally or two times more active than ofloxacin. Such in-vitro results are promising, and clinical trials are warranted. Conversely, in-vitro results relating to the bactericidal activity of levofloxacin against C. burnetii do not necessarily indicate a therapeutic benefit in using this antibiotic to treat patients with chronic Q fever.
